Adjuvant immunotherapy improves melanoma outcomes

Bookmark and Share
Published: 8 Oct 2016
Views: 1220
Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France

Prof Eggermont presents, at a press conference at ESMO 2016, the finding that ipilimumab as adjuvant therapy significantly improve overall survival in patients with high risk stage III melanoma, according to the Phase III trial.

Watch the interview or read the news story for more.

  • Categories: